Inve India ▾

RPG Life Sciences share price & results

RPG Life Sciences Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Integrated pharma maker of branded formulations, generic exports & synthetic APIs; immunosuppressant segment leader.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue196 ₹ crore+16.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin22.0 %+1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit31.0 ₹ crore+19.2% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity20.66 %−2.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-1.27 %−24.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable—Trailing twelve monthsTTM to Jun 2026Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 6 judged targets kept · 7 open · verdicts reflect calls analysed to Q4 FY26.

RPG Life Sciences Limited management guidance track record on Inve: 13 targets tracked across analysed earnings calls (2 achieved, 4 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
API Plant RestorationRestoration by September/October, normalization from H2 FY26
Call transcript, Q4 FY25 · 29 Apr 2025		Q4 FY25Q4 FY26:The API segment demonstrated a strong recovery in Q4 with revenues of INR 33.3 crores (144% growth) and management confirmed margin stabilization has started, indicating the plant is fully operational and business normalized in H2 FY26 as targeted.
Call transcript, Q4 FY26 · 30 Apr 2026		Achieved
Domestic Market Value Growthmid-teens for FY26
Call transcript, Q4 FY25 · 29 Apr 2025		Q4 FY25Q4 FY26:Full year FY26 domestic formulation growth was 13.7%. This is slightly below the 'mid-teens' (14-16%) guidance.
Call transcript, Q4 FY26 · 30 Apr 2026		Missed
New API Molecules Pipelinearound 12 by end FY26 and FY27
Call transcript, Q4 FY25 · 29 Apr 2025		Q4 FY25Q4 FY26:Management confirmed the API pipeline has expanded to 13 products, aligning with the target of launching ~12 new molecules by the end of FY26/FY27.
Call transcript, Q4 FY26 · 30 Apr 2026		On Track

Source: Inve Guidance Tracker for RPG Life Sciences Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of RPG Life Sciences Limited's 13 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 10 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,836.1 +2.69% · +₹74.4

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +20.4% 1Y

₹2.0k₹2.5k₹3.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 24 Oct 2025Q4 FY26 — 30 Apr 2026

1Y: ₹2,354.8 on 24 Oct 2025 → ₹2,836.1. High ₹3,089.2 (29 Sept 2026), low ₹1,744 (23 Mar 2026).

Previous close
₹2,761.7
Market cap
₹4.6k Cr
52-week range
₹1,744 – ₹3,089.2
One year
+19.11%
Price to earnings (TTM to Jun 2026)
38.97×
Return on equity (TTM to Jun 2026)
20.66%

Overview

Symbol
NSE:RPGLIFE
Exchange
NSE
Currency
INR

What RPG Life Sciences Limited does

Based on the company's own presentations, annual report and earnings calls.

RPG Life Sciences is an integrated research-based pharmaceutical company that develops, manufactures and markets branded formulations for the Indian and Nepal markets, oral solid generic and branded-generic formulations for regulated and emerging export markets, and high-value synthetic APIs. It operates three manufacturing facilities in Ankleshwar (Gujarat) and Navi Mumbai (Maharashtra) making formulations and APIs, supported by warehouses in Ankleshwar and Ghaziabad. Its Domestic Formulations business sells branded drugs to physicians across acute, chronic and specialty therapy areas, its International Formulations business exports generics and branded generics to over 50 countries, and its API business supplies niche synthetic APIs to global generic and pharma companies while also backward-integrating supply for its own formulations. The company holds a leadership position in the immunosuppressant segment both domestically and internationally, anchored by flagship product Azathioprine.

Segments

  • Domestic Formulations (DF)
  • International Formulations (IF)
  • APIs
Employees
1,300+
Manufacturing facilities
3 (2 formulation units in Ankleshwar, 1 API unit in Navi Mumbai)
Countries with market presence
50+
Market position
Leader in the immunosuppressant segment, domestic and international
Legacy "Textbook" brands
6
Therapy areas represented by high-equity brands
9
Headquarters Mumbai, MaharashtraEmployees 1,300 (FY26 (Apr 2026 investor ) Company website

How the price took the results

close before → close after

Q4 FY26
+13.0%
30 Apr

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for RPG Life Sciences Limited

Free account: one company. Everything above stays public.

Write why you follow RPG Life Sciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse RPG Life Sciences Limited

Guides on how to read this kind of business and the numbers that matter.